Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BiomX ( (PHGE) ) just unveiled an update.
On January 13, 2026, the company completed a previously announced private placement of its securities under a Securities Purchase Agreement dated December 26, 2025, and in connection with that closing expanded its board to nine members and appointed investment professional Reuven Yeganeh as an independent Class 1 director, with a term running until the 2027 annual meeting, subject to certain ownership conditions. Also on January 13, 2026, the company entered into a standard-form indemnification agreement with Yeganeh and filed a Certificate of Designations in Delaware establishing its Series Y Convertible Preferred Stock, issuing 3,300 preferred shares alongside warrants for common stock, a move that refines its capital structure and adds experienced financial oversight at the board level.
The most recent analyst rating on (PHGE) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.
Spark’s Take on PHGE Stock
According to Spark, TipRanks’ AI Analyst, PHGE is a Neutral.
The score is held down primarily by weak financial performance (minimal revenue, persistent losses and cash burn) and bearish technical trends (well below major moving averages with negative MACD). Offsetting factors are limited to modest balance-sheet leverage improvement and a cautiously positive clinical/regulatory outlook, though near-term liquidity needs and recent negative corporate developments keep the risk profile elevated.
To see Spark’s full report on PHGE stock, click here.
More about BiomX
Average Trading Volume: 87,201
Technical Sentiment Signal: Sell
Current Market Cap: $3.43M
For detailed information about PHGE stock, go to TipRanks’ Stock Analysis page.